Rabbit Anti-Human TAT (C-terminal) Polyclonal antibody

Tumor cell internalization and controlling drug release are two major biological barriers, which limit the clinical application of chemotherapeutic drugs. To address these obstacles, an effective redox-responsive TAT-DSPE-PEG/PEI-SS-PLA/DOX (shorten as TPSPD) nanoparticle was designed in this paper. Doxorubicin (DOX) was incorporated with polyethylenemine-disulfide bond-polylactic acid (PEI-SS-PLA/DOX) to form the core of nanoparticles, while the TAT peptide modifided-1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide-(polyethylene glycol)(5000) (TAT-PEG-DSPE) was as the shell. Nanoparticles presented proper particle size and suitable serum stability as well as the long circulation time. Moreover, TPSPD nanoparticles enhanced the cellular uptake rate and realized the controlled drug release at the tumor site. In vivo experiments showed that TPSPD possessed favorable antitumor activity and reduced the systemic toxicity. Altogether, the prepared TPSPD nanoparticle was expected to be a promising strategy in cancer therapy.

Background: There is limited data evaluating the prescription practices for antithrombotic therapy in patients with atrial fibrillation (AF) following elective percutaneous coronary intervention (PCI). Objective: This single-center, single-operator, retrospective cohort study aimed to evaluate trends of antithrombotic treatment strategies in patients with AF undergoing elective PCI. Methods: Patients with AF who electively underwent PCI performed by a single interventionalist between April 2013 and May 2018 were identified. The primary outcome was the antithrombotic therapy at discharge assessed by chart review: triple (TAT, triple antithrombotic therapy) or dual (DAT, dual antithrombotic therapy) antithrombotic therapy and vitamin K antagonist (VKA) or non-vitamin K antagonist oral anticoagulant (NOAC), respectively. Results: Of 6,135 screened patients, 259 met the inclusion criteria. Among these, 133 (51%) patients received NOAC- and 126 (49%) VKA-therapy. Compared with patients on NOAC therapy, patients treated with VKA had higher bleeding risk (mean HAS-BLED-Score; 2.3 vs. 2.0; p = 0.02) and more co-morbidities (estimated glomerular filtration rate <30 ml/min, 11 vs. 4%; p = 0.04; diabetes mellitus, 33 vs. 20%; p = 0.03; history of previous PCI, 37 vs. 21%; p < 0.01). TAT was prescribed more frequently if the prescription included VKA compared with NOAC (61 vs. 41%; p < 0.01). Prescription of TAT and VKA decreased throughout the observed period (2013: 100% vs. 2018: 6%; p < 0.01 and 2013: 91% vs. 2018: 28%; p < 0.01). Conclusion: These observational data from a single center registry show a decrease of TAT- and VKA- prescription in favor of DAT with NOAC. Whether these observations are consistent with national or global trends should to be evaluated in further studies.